Ionis Reports Second Quarter 2018 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. TMUS
6. PEP
7. AXP
8. SPY
9. CVS
10. UNH

Go back to Ionis Reports Second Quarter 2018 Financial Results

Ionis Pharmaceuticals (IONS) Misses Q2 EPS by 20c, Revenues Miss

August 7, 2018 7:14 AM EDT

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.29), $0.20 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $118 million versus the consensus estimate of $135.48 million.

"With the approval of TEGSEDI in Europe, Ionis is entering a new chapter as a multi-product, sustainably profitable company. We anticipate the approval and launch of TEGSEDI and WAYLIVRA in multiple markets this year," said Stanley T. Crooke, M.D., Ph.D., chairman of the board and chief executive officer of Ionis.... More